By Lina carolina 
A groundbreaking study, leveraging a pioneering computational tool developed by researchers at University College London (UCL) and the Francis Crick Institute, has revealed a profound link between the abundance of immune cells in cancer patients’ blood and their survival rates. This innovative technique, named Immune Lymphocyte Estimation from Nucleotide Sequencing (ImmuneLENS), enables scientists to quantify T cells and B cells – crucial components of the immune system – directly from whole genome sequencing (WGS) data for the first time. This breakthrough promises to revolutionize how cancer is understood, diagnosed, and treated by providing clinicians with readily accessible prognostic information.
Unveiling the Immune Landscape Through Whole Genome Sequencing
Whole genome sequencing (WGS) involves a comprehensive analysis of an individual’s complete DNA, offering a detailed blueprint of their genetic makeup. This powerful technology has become indispensable in medical research, providing critical insights into genetic predispositions, disease mechanisms, and the body’s intricate responses to illness, particularly in complex conditions like cancer. Traditionally, the detailed cellular composition of the immune system, especially the proportion of circulating immune cells, has required separate, often laborious, analytical methods. ImmuneLENS changes this paradigm by extracting this vital information from existing WGS data, which is increasingly being collected as part of large-scale genomic initiatives.
The development of ImmuneLENS addresses a long-standing challenge in cancer research: understanding the systemic impact of the immune system on cancer progression. While much research has historically focused on the immune cells directly within the tumor microenvironment, the circulating immune cells in the bloodstream represent the body’s broader immune surveillance and response capacity. The ability to analyze these peripheral immune cells from WGS data, which is becoming more widely available, opens up unprecedented avenues for research and clinical application.
Pioneering Analysis of the 100,000 Genomes Project
The research team applied ImmuneLENS to an extensive dataset of over 90,000 WGS samples drawn from the 100,000 Genomes Project. This ambitious initiative, spearheaded by Genomics England and NHS England, has been instrumental in collecting and analyzing the genomes of a diverse population, including individuals with rare diseases and cancer patients, alongside healthy controls. By integrating ImmuneLENS with this rich dataset, researchers gained a unique vantage point to explore the intricate interplay between the immune system and cancer across a broad spectrum of individuals.
The initial findings from this large-scale analysis were striking. Cancer patients, on average, exhibited a lower proportion of circulating T cells in their blood compared to their healthy counterparts. This observation alone suggested a potential immune dysregulation associated with the disease. However, the study went further, demonstrating that the proportion of T cells in the blood served as a robust predictor of cancer outcomes.
T-Cell Proportions as a Powerful Prognostic Indicator
The study revealed a significant correlation between higher proportions of T cells in the blood and improved survival rates for cancer patients. Specifically, individuals with a greater number of circulating T cells experienced a remarkable 47% reduction in deaths over a five-year period following surgery. This association remained statistically significant even after accounting for crucial confounding factors such as age, the stage of the cancer, and across all investigated cancer types. This finding underscores the pivotal role of the peripheral immune system in shaping a patient’s prognosis and suggests that blood-based immune cell counts could become a vital component of cancer risk assessment and management.
Professor Nicholas McGranahan, a senior author of the study from the UCL Cancer Institute, emphasized the transformative potential of ImmuneLENS. "Most immune system analysis until now has focused on the tumour itself," Professor McGranahan stated. "So, the results we’re seeing using this new technique—which examines the number of immune cells in a person’s blood—are of considerable interest. What’s going on with immune cells in the blood seems to have a huge impact on cancer survival and may be able to predict how long a cancer patient will survive better than the number of T cells in the tumour alone."
He further elaborated on the scale of the discovery: "There have been hints in previous research that this might be important, but being able to analyse immune system information at this scale is game-changing. The ability to compare immune cell changes in the blood and to what’s happening in the tumour environment opens up new avenues for cancer research, as well as healthcare research more widely."
Integrating Immune Insights into Clinical Diagnostics
The researchers propose that the biological markers identified through ImmuneLENS could be seamlessly integrated into existing genetic diagnostic tests. This integration would provide clinicians with a more comprehensive understanding of a patient’s disease, enabling them to make more informed decisions regarding treatment strategies. By having readily available information about a patient’s immune status, doctors could potentially tailor therapies, such as immunotherapy, to better match an individual’s immune profile.
"In terms of patient diagnosis and treatment, knowing whether a patient has relatively high or low numbers of immune cells in the blood, and how this corresponds to their prognosis, could help clinicians to decide on the best course of treatment for the individual," Professor McGranahan added. This move towards personalized medicine, driven by advanced genomic and immunological insights, represents a significant leap forward in the fight against cancer.
The Complex Dance Between Cancer and the Immune System
Cancer, fundamentally a disease driven by genetic mutations within cells, often develops mechanisms to evade the immune system’s surveillance. While immune cells are equipped to recognize and eliminate abnormal cells, tumors can evolve to suppress or evade this immune response, leading to immune dysregulation. Understanding both the local immune environment within the tumor and the broader immune status of the patient is therefore critical for comprehending cancer development and predicting treatment efficacy.
The 100,000 Genomes Project, by providing access to a vast repository of WGS data, has enabled researchers to examine the full spectrum of genetic alterations in both healthy and cancerous cells. However, the precise immune cell composition within these samples, particularly in the periphery, remained largely inaccessible until the development of tools like ImmuneLENS. This new capability allows for a more holistic view of the patient’s interaction with their cancer.
A Legacy of Innovation: Building on Previous Work
ImmuneLENS builds upon prior advancements in computational immunology. A previous method, developed in 2021, had enabled the calculation of T-cell proportions from whole exome sequencing (WES) data. ImmuneLENS expands this capability to whole genome sequencing, offering a more comprehensive analysis and the ability to distinguish between different types of immune cells, including various subtypes of B cells.
Age-Related Immune Decline and Cancer
The study also shed light on the age-related decline of immune cells in the blood, a known phenomenon in healthy individuals. However, the research found that this decline appears to occur sooner in individuals with cancer. This observation could suggest a more rapid depletion or suppression of immune function in the presence of malignancy.
Interestingly, the study noted that this accelerated immune cell decline was more pronounced in male cancer patients compared to female patients. While the precise reasons for these sex-based differences remain unclear, it raises questions about potential hormonal or genetic factors influencing immune responses to cancer and their impact on survival. Further research is needed to elucidate these disparities and their clinical implications.
B-Cell Signatures and Early Cancer Detection
Beyond T cells, the research also explored the role of B cells, another critical component of the immune system. The study found that individuals who appeared healthy at the time of their WGS sample collection, but subsequently developed cancer, often had lower-than-average levels of B cells in their blood. This finding has significant implications for early cancer detection. It could indicate the presence of undiagnosed early-stage cancer or pre-cancerous immune system changes that might serve as an early warning sign.
The potential for using B-cell levels as an indicator for early cancer detection is a promising avenue for future research. Moreover, understanding these pre-clinical immune alterations could provide valuable insights into the mechanisms that contribute to cancer development.
A New Paradigm for Immune Cell Analysis
Dr. Robert Bentham, the first author of the study from the UCL Cancer Institute, described the innovative approach of ImmuneLENS: "Lots of approaches that measure immune cells from genetic data are like looking for a needle in a haystack. Our approach in this study instead looks at the haystack itself and asks how the presence of immune cells changes its overall shape. It’s a different, more efficient way of finding the needle."
This analogy effectively captures the shift in methodology. Instead of trying to isolate and count individual immune cells within complex genetic data, ImmuneLENS analyzes the broader patterns and alterations in the WGS data that are indicative of the presence and quantity of immune cells. This "haystack" approach allows for the interrogation of vast amounts of existing WGS data that were previously inaccessible for detailed immune analysis.
"One of the things this will allow us to do is to build significant immune datasets using data we already have from the many large-scale WGS cohorts but haven’t been able to interrogate until now," Dr. Bentham explained. "It will allow researchers to explore what’s happening in the immune system during health and disease, not just in cancer but potentially in many areas of medicine."
Distinguishing B-Cell Subtypes and Their Prognostic Value
ImmuneLENS also offers the ability to differentiate between various types of B cells, a capability that has been challenging with previous methods. B cells are responsible for producing antibodies, which are crucial for neutralizing pathogens and abnormal cells. As B cells mature, they specialize to produce specific types of antibodies. The researchers exploited this specialization process to identify and classify B cells.
When applied to WGS data, this advanced analysis revealed that B cells producing IgM/D antibodies—which are typically generated upon the initial encounter with a foreign antigen—were the only B-cell subtype associated with improved survival outcomes in cancer patients. This suggests that these particular B cells may play a significant role in anti-tumor immunity. Their presence and activity could serve as a novel biological marker for cancer diagnosis and a promising target for future therapeutic interventions.
Translating Discoveries into Clinical Practice
The next crucial step for the research team involves translating these discoveries into tangible clinical applications. They are optimistic that these newly identified biological markers can be incorporated into the current battery of cancer diagnostic tests at minimal to no additional cost. Professor McGranahan and his team have already secured a Cancer Research UK (CRUK) funded Biomarker Project Award to facilitate this translation.
This advancement is particularly significant for predicting patient response to immunotherapy. While the proportion of T cells within a tumor is a recognized biomarker, it cannot be routinely measured using standard genomic tests. ImmuneLENS offers a potential solution by providing this critical information from readily available WGS data.
Dr. Nisharnthi Duggan, Research Information Manager at Cancer Research UK, expressed enthusiasm for the ongoing work. "Cancer Research UK is pleased to support this ongoing work investigating whether measuring immune cell levels in our blood can help predict cancer survival," she stated. "We’re living in a golden age of research where we can use patient data in sophisticated ways to help us better understand cancer and how to beat it."
She added, "Further research is needed, but this could one day become a tool to help doctors personalize treatment for people with cancer." This sentiment highlights the collaborative effort and the shared vision for advancing cancer care through cutting-edge research.
The research is a key component of the Cancer Research UK-funded TRACERx project, underscoring the commitment of major cancer research organizations to pushing the boundaries of understanding and treatment. Furthermore, the accessibility of data from the 100,000 Genomes Project, managed by Genomics England, has been pivotal in enabling these groundbreaking discoveries. This symbiotic relationship between large-scale data initiatives and innovative analytical tools is paving the way for a new era in precision oncology.